ABBV-1042

Phase 1Small molecule

AbbVie

ABBV-1042 is one of 5 small molecule programs targeting Adverse Events. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adverse EventsRecruiting

Adverse EventsPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Adverse Events

#DrugCompanyPhaseTrials

Penehyclidine Inhalation

PPeking University First Hospital

Phase 3

1 2

ABBV-8736

AbbVie

Phase 1

1 3

ABBV-142

AbbVie

Phase 1

1 4

ABBV-1042

AbbVie

Phase 1

1 5

Glifage

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adverse Events1 trial

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

Recruiting· AbbVie logo

AbbVie·Phase 1·NCT07222709·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ABBV-1042. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABBV-1042 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABBV-1042. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AbbVie

ABBV-1042

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adverse Events1 trial

References

Drug Info

Quick Facts

Related News